Thomas Stankovich - Aug 4, 2023 Form 4 Insider Report for ReShape Lifesciences Inc. (RSLS)

Role
Chief Financial Officer
Signature
/s/ Thomas Stankovich
Stock symbol
RSLS
Transactions as of
Aug 4, 2023
Transactions value $
-$386
Form type
4
Date filed
11/8/2023, 04:16 PM
Previous filing
Jul 19, 2023
Next filing
Aug 13, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RSLS Common Stock, $0.001 par value per share Sale -$154 -108 -0.46% $1.43 23.3K Aug 4, 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale -$55 -39 -0.17% $1.42 23.2K Aug 24, 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale -$105 -118 -0.51% $0.89 23.1K Sep 1, 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale -$36 -39 -0.17% $0.93 23.1K Oct 11, 2023 Direct F1
transaction RSLS Common Stock, $0.001 par value per share Sale -$35 -131 -0.57% $0.27 22.9K Oct 25, 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On July 22, 2021, Mr. Stankovich was awarded an aggregate of 7,455 restricted stock units, all of which, including the unvested portion, were reported on a Form 4 filed on September 17, 2021. The shares reported under this Form 4 as being disposed of were sold to cover taxes in connection with the vesting of a portion of those previously reported restricted stock units.